TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17405474

Group type: EXPERIMENTAL
Intervention: Renewed generation VICRYL rapide (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Original generation VICRYL rapide (n = 60)
Number of subjects: 120
Study: 10799351

Group type: EXPERIMENTAL
Intervention: Octreotide 200 microgram s.c. 3 times daily, starting the night before endoscopic procedures
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo 3 times daily, starting the night before endoscopic procedures
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 8851809

Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Hispanic abstainers
Number of subjects: 1919

Group type: COMPARATOR
Intervention: Non-Hispanic Whites
Number of subjects: 1919
Study: 1381640

Group type: EXPERIMENTAL
Intervention: Teicoplanin, 400 mg i.v., given as a single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 6387059

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Adriamycin, Cisplatin (CAP) followed by Cyclophosphamide, 5-Fluorouracil, Prednisone (CFP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cyclophosphamide, 5-Fluorouracil, Prednisone (CFP)
Number of subjects: 86
Study: 30523756

Group type: EXPERIMENTAL
Intervention: Cisplatin and Etoposide with Veliparib (CE+V)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cisplatin and Etoposide with Placebo (CE+P)
Number of subjects: 128
Study: 30388039

Group type: EXPERIMENTAL
Intervention: ACL-deficient condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ACL-/ALL-deficient condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5-N·m load after ACL and ALL sectioning
Number of subjects: 8

Group type: COMPARATOR
Intervention: Supra- and inframeniscal ALL sectioning
Number of subjects: 8
Study: 26063054

Group type: EXPERIMENTAL
Intervention: Good sleep at baseline
Number of subjects: 409

Group type: COMPARATOR
Intervention: Impaired sleep at baseline
Number of subjects: 409
Study: 24901761

Group type: EXPERIMENTAL
Intervention: Dynamic postural stability training program using the Biodex Stability System
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 30
Study: 23157899

Group type: EXPERIMENTAL
Intervention: HIFU
Number of subjects: 72

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: TACE + HIFU
Number of subjects: 72
Study: 20141299

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlisted Controls
Number of subjects: 0
Study: 17622289

Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control diet with exercise (CONEx)
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-protein diet (HP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-protein diet with exercise (HPEx)
Number of subjects: 44
Study: 16122283

Group type: EXPERIMENTAL
Intervention: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with water (regimen B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with enteral feeding (regimen C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intact moxifloxacin 400 mg tablet (regimen A, reference treatment)
Number of subjects: 12
Study: 11849412

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acute rejection episodes
Number of subjects: 51

Group type: COMPARATOR
Intervention: No acute rejection episodes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 3 months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6 months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 12 months
Number of subjects: 51
Study: 10402079

Group type: EXPERIMENTAL
Intervention: Topical application of 30 mg ketoprofen plaster (n = 40)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple applications of 30 mg ketoprofen plaster for 5 days (n = 30)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral intake of 50 mg ketoprofen (n = 30)
Number of subjects: 100
Study: 7594331

Group type: EXPERIMENTAL
Intervention: Lansoprazole injection 30 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole injection 30 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole injection 15 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histamine H2-receptor antagonist 20 mg twice daily
Number of subjects: 20
Study: 2379945

Group type: EXPERIMENTAL
Intervention: Low sodium diet (5-40 mmol/24 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal sodium diet (160-200 mmol/24 hours)
Number of subjects: 12
Study: 31896035

Group type: EXPERIMENTAL
Intervention: Branching path simulation training
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional lectures (Control)
Number of subjects: 102
Study: 28207546

Group type: EXPERIMENTAL
Intervention: Room-temperature water immersion (RWI)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ice-water immersion (IWI)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No water immersion (Control)
Number of subjects: 53
Study: 24413368

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 23013440

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 1009
Study: 22182865

Group type: EXPERIMENTAL
Intervention: Continuous intercostal nerve block (CINB) with 0.2% ropivacaine infusion
Number of subjects: 102

Group type: COMPARATOR
Intervention: Historical control using epidural analgesia
Number of subjects: 102
Study: 21092270

Group type: EXPERIMENTAL
Intervention: CRA feeding prior to allergen sensitization and challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBS feeding
Number of subjects: 0
Study: 17603390

Group type: EXPERIMENTAL
Intervention: Intermittent sampling at 7- to 14-day intervals
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Recall period of 48 hours
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Continuous surveillance
Number of subjects: 10000
Study: 14759615

Group type: EXPERIMENTAL
Intervention: Cyclofem (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NET-EN (norethisterone enanthate 200 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both Cyclofem and NET-EN
Number of subjects: 100
Study: 11772793

Group type: EXPERIMENTAL
Intervention: Preoperative thoracic epidural analgesia (TEA) with bupivacaine and morphine solution, postoperative epidural PCA
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Postoperative thoracic epidural analgesia (TEA) with bolus dose
Number of subjects: 69

Group type: COMPARATOR
Intervention: IV patient‐controlled analgesia (IV‐PCA) with morphine
Number of subjects: 69
Study: 9690692

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (group 1 and group 2)
Number of subjects: 60
Study: 7806092

Group type: EXPERIMENTAL
Intervention: Congo red positive patients (9 out of 62)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Congo red negative patients
Number of subjects: 62
Study: 2668978

Group type: EXPERIMENTAL
Intervention: Minaprine 400 mg daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 403395

Group type: EXPERIMENTAL
Intervention: Combined treatment with radiotherapy (5000 rads) and ICRF 159 (250 mg p.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiotherapy alone (5000 rads)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined treatment with radiotherapy and ICRF 159
Number of subjects: 40
Study: 30442024

Group type: EXPERIMENTAL
Intervention: Risk Reduction Therapy for Adolescents (RRTA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Both RRTA and TAU
Number of subjects: 105
Study: 28893464

Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane [BPU] dressing, sutureless securement device)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Integrated securement dressings (ISDs)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (TA) plus BPU dressing
Number of subjects: 101
Study: 27136912

Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg under high-fat breakfast conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg under low-fat breakfast conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fedratinib 100 mg under high-fat breakfast conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg under fasted conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 0
Study: 23873570

Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with 125 µg OMP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with OMP+NP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with OMP only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with or without NP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with 125 µg OMP alone and OMP+NP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other groups (not specified)
Number of subjects: 0
Study: 21735362

Group type: EXPERIMENTAL
Intervention: Nutri‐Learn buffet (NLB)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional counselling tools (pictures and tables)
Number of subjects: 134
Study: 19371311

Group type: EXPERIMENTAL
Intervention: Morphine infusion at 30 microg min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine infusion at 100 microg min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine infusion at 50 microg min(‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine with antihistamines pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine with nitric oxide clamp
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine alone
Number of subjects: 0
Study: 16049190

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) study with a delayed naming task
Number of subjects: 0
Study: 12631527

Group type: EXPERIMENTAL
Intervention: Spelling performance task (sub‐word‐level and lexical route)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Longitudinal testing after 6-12 months
Number of subjects: 23
Study: 10696747

Group type: EXPERIMENTAL
Intervention: Subconjunctival mydricaine and topical diclofenac 0.1%
Number of subjects: 57

Group type: COMPARATOR
Intervention: Subconjunctival mydricaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Topical diclofenac 0.1%
Number of subjects: 57
Study: 9186240

Group type: EXPERIMENTAL
Intervention: Contingent negative variations (CNVs) recorded from subdural electrodes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bereitschaftspotentials (BPs) recorded from subdural electrodes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Late CNVs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Potentials observed after S2
Number of subjects: 14
Study: 8471328

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) and Vindesine (VDS) with MER
Number of subjects: 103

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) and Vindesine (VDS) without MER
Number of subjects: 103
Study: 3492759

Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim twice a day
Number of subjects: 74

Group type: COMPARATOR
Intervention: 160 mg trimethoprim plus 800 mg sulphamethoxazole twice a day
Number of subjects: 74
Study: 31981972

Group type: EXPERIMENTAL
Intervention: Traditional face‐to‐face teaching
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: E‐learning
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 296
Study: 29573143

Group type: EXPERIMENTAL
Intervention: Q/LAIV
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1301
Study: 27448816

Group type: EXPERIMENTAL
Intervention: Third-generation cryoballoon
Number of subjects: 74

Group type: COMPARATOR
Intervention: Second-generation cryoballoon
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 24945884

Group type: EXPERIMENTAL
Intervention: Health communication intervention (face-to-face education and booster call)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study: 22732846

Group type: EXPERIMENTAL
Intervention: Sublingual ketorolac (10 mg 4 times daily)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam (20 mg once daily)
Number of subjects: 47
Study: 20683319

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enfuvirtide
Number of subjects: 60
Study: 19020158

Group type: EXPERIMENTAL
Intervention: TAP block with ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 50
Study: 15932840

Group type: EXPERIMENTAL
Intervention: Prostaglandin F(2alpha) + ATP (0.45 nmol/min, intravenously)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Prostaglandin F(2alpha) (7.5 mug/min, intravenously)
Number of subjects: 34
Study: 12074779

Group type: EXPERIMENTAL
Intervention: Multivariate risk model using total PSA, percentage of free PSA, prostate volume, and DRE findings
Number of subjects: 758

Group type: COMPARATOR
Intervention: Percentage of free PSA
Number of subjects: 758

Group type: COMPARATOR
Intervention: Total PSA, prostate volume, and DRE findings
Number of subjects: 758

Group type: COMPARATOR
Intervention: Age and family history of prostate cancer
Number of subjects: 758
Study: 9523857

Group type: EXPERIMENTAL
Intervention: Drinking water with less than 1.57 micromol/l (<0.1 mg/l)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Drinking water with 31.48 micromol/l (2 mg/l) of copper
Number of subjects: 128
Study: 8590557

Group type: EXPERIMENTAL
Intervention: Exposure to 3300 lux of cool-white fluorescent light for either 1 h or 15 min in the morning for 2 weeks (Intervention)
Number of subjects: 18
Study: 2568660

Group type: EXPERIMENTAL
Intervention: Triprolidine (7.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 798330

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone therapy at the time of kidney transplantation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 31448392

Group type: COMPARATOR
Intervention: Corticosteroid injections (triamcinolone in 2% xylocaine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 80
Study: 29272063

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemia (assessed by hypo-score)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemia (T2)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemia (T3)
Number of subjects: 1441
Study: 27424013

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (3 days per week for 3 months, 36 sessions total, 45 minutes each session)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 0
Study: 23730848

Group type: EXPERIMENTAL
Intervention: BFR-RT
Number of subjects: 19

Group type: COMPARATOR
Intervention: CON
Number of subjects: 19
Study: 22543001

Group type: EXPERIMENTAL
Intervention: Immediate exposure to training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Delayed exposure to training
Number of subjects: 39
Study: 20591206

Group type: EXPERIMENTAL
Intervention: Very-long-chain inulin (VLCI) 10 g/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Maltodextrin (placebo) 10 g/d
Number of subjects: 32
Study: 18019992

Group type: EXPERIMENTAL
Intervention: Femoral component placed parallel to the epicondylar axis (computer assisted group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral component placed in 3 degrees external rotation to the posterior condylar axis (control group)
Number of subjects: 60
Study: 16214044

Group type: EXPERIMENTAL
Intervention: Industry-sponsored RCTs
Number of subjects: 655
Study: 12153966

Group type: EXPERIMENTAL
Intervention: Smoking intervention plus Atrovent inhaler (SI-A) group, received ipratropium bromide
Number of subjects: 149

Group type: COMPARATOR
Intervention: Smoking intervention plus placebo inhaler (SI-P) group, received placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: All participants considered with smoking status as a time-dependent covariate
Number of subjects: 149
Study: 10320256

Group type: EXPERIMENTAL
Intervention: Retrograde cerebral perfusion (RCP)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Selective cerebral perfusion (SCP)
Number of subjects: 5
Study: 8578060

Group type: EXPERIMENTAL
Intervention: Gabapentin as add-on therapy; different dosages not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 0
Study: 1924663

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6123647

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (assumed benefit for rapid growth stratum)
Number of subjects: 164
Study: 31762024

Group type: EXPERIMENTAL
Intervention: Instant brown rice (IBR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Refined maize ugali (RMU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole maize ugali (WMU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole grain pilaf (WGP)
Number of subjects: 14
Study: 29229000

Group type: EXPERIMENTAL
Intervention: Self-administered, computerized SBIRT intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Clinician-administered SBIRT intervention
Number of subjects: 208
Study: 26486976

Group type: EXPERIMENTAL
Intervention: FACETS programme
Number of subjects: 72
Study: 23963438

Group type: EXPERIMENTAL
Intervention: Sprint interval training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Continuous aerobic training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 22176767

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 20672447

Group type: EXPERIMENTAL
Intervention: Vicriviroc 5 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vicriviroc 10 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vicriviroc 15 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vicriviroc (all doses)
Number of subjects: 118
Study: 17933470

Group type: EXPERIMENTAL
Intervention: Public speaking stress
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: In vitro beta-adrenergic stimulation of PBCs
Number of subjects: 22
Study: 16244538

Group type: EXPERIMENTAL
Intervention: GH + Gln placebo + diet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GH + Gln + diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gln + diet
Number of subjects: 41
Study: 12323178

Group type: EXPERIMENTAL
Intervention: High-level dissection group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-level dissection group
Number of subjects: 35
Study: 10546931

Group type: EXPERIMENTAL
Intervention: 25 microg of intravitreal TPA in buffered salt solution (BSS) 15 minutes before vitrectomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: BSS alone
Number of subjects: 56
Study: 7477217

Group type: EXPERIMENTAL
Intervention: 25 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 100 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 300 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 100 mg or 300 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy
Number of subjects: 32
Study: 2124651

Group type: EXPERIMENTAL
Intervention: Branched chain amino acid (BCAA) administration postoperatively in gastrectomized rats and in humans after subtotal or total gastrectomy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional total parenteral nutrition with a Calorie/N ratio of about 150.
Number of subjects: 0
Study: 7047460

Group type: EXPERIMENTAL
Intervention: Micrainin (meprobamate-acetylsalicylic acid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aspirin (acetylsalicylic acid)
Number of subjects: 16
Study: 31260548

Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 2: Imitation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 1: Relating to People
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 5: Object Use
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 4: Body Use
Number of subjects: 53
Study: 29144879

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both interventions (35% hydrogen peroxide and 37% carbamide peroxide)
Number of subjects: 50
Study: 25316378

Group type: EXPERIMENTAL
Intervention: Selective patellar resurfacing
Number of subjects: 350

Group type: COMPARATOR
Intervention: No resurfacing (control group)
Number of subjects: 350